Hikma announces licensing agreement with Takeda

RNS Number : 2206O

Hikma Pharmaceuticals Plc

17 August 2017

 

PRESS RELEASE

Hikma announces new licensing agreement with Takeda for products in the Middle East and North Africa

·     Enhances MENA product offering in strategic therapeutic areas

·     Reinforces commitment to provide high-quality medicines to patients

London, 17 August 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational pharmaceutical group, today announces that through its wholly owned subsidiary Hikma Pharmaceuticals LLC, it has agreed to expand its licensing and distribution agreement with Takeda Pharmaceutical Company Limited (Takeda), a global, research and development-driven pharmaceutical company, adding new products to its portfolio in the Middle East and North Africa (MENA).

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive patient access for Takeda's products.  We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region.  By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines."

Danilo Cassani, Vice President and Area Head Near East, Middle East & Africa added, "At Takeda, we put patients at the centre of everything we do. As such, our partnership with Hikma is a testament of our commitment to offer patients world-class cardiovascular and metabolism (CVM) medicines while keeping focus on our core therapeutic areas of oncology and gastroenterology.  This will help better serve the unmet medical needs of patients."

Under the terms of the agreement:

·	Hikma has been granted the exclusive rights to manufacture and commercialise three of Takeda's leading primary care product families - Vipedia™ (alogliptin), including Vipdomet™ (alogliptin/metformin) and Incresync™ (alogliptin/pioglitazone) (anti-diabetic), Edarbi™ (azilsartan), including Edarbyclor™ (azilsartan/chlorothalidone) (anti-hypertensive) and Xefo™ (lornoxicam) in its rapid form (anti-inflammatory/ pain) - in its MENA markets1
·	Hikma has also been granted the exclusive rights to manufacture and commercialise Takeda's Dexilant™ (dexlansoprozole) (gastric acid secretion inhibitor) in its MENA markets, with the exception of Saudi Arabia, UAE and Egypt
·	Hikma's existing license agreement with Takeda in respect of Xefo™ (lornoxicam) tablets (anti-inflammatory/ pain), has been expanded beyond Saudi Arabia and Jordan to cover Hikma's other MENA markets

The new agreement builds on a long-standing strategic partnership between Hikma and Takeda.  The relationship leverages Hikma's substantial sales and manufacturing presence in MENA and extensive experience of building brands in the region.

¹The agreement does not include the Egyptian market for Vipedia™

-- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal	VP Corporate Strategy and Investor Relations	[phone]/ [phone]
Lucinda Baker	Deputy Director of Investor Relations	[phone]/ [phone]

FTI Consulting  

Ben Atwell/ Brett Pollard

[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: 'Injectables,' 'Generics' and 'Branded, based principally in the United States, the Middle East and North Africa (MENA) and Europe.  In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million.  For more information visit www.hikma.com.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

 

END

 

 

NRADMGMRFVFGNZZ